In October 2024, Indaptus achieved a key milestone when it announced a clinical supply agreement with BeiGene to advance the evaluation of Decoy20 in combination with their PD-1 checkpoint inhibitor, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback